Ageism And Prescribing In the Elderly: UK Report

18 May 1997

Patients aged over 65 are potentially the greatest beneficiaries ofappropriate, optimal drug therapy, but they also suffer much drug-related iatrogenic disease due to inappropriate treatment, according to a new study published by the Royal College of Physicians.

The over-65s make up only 18% of the UK population but receive 45% of all prescription items, 78% of which are repeats. Patients should be individually assessed for capacity to benefit from treatment, irrespective of age, the RCP stresses.

Doctors should think carefully before prescribing, says the report, adding that they should also: - take a thorough history of the patient, including medication; - have a clear plan for introducing drug therapy (usually "start low and go slow"); and, most importantly, - give clear information to the patient and check that they understand the need for the medicine and the possible side effects.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight